Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.59 |
| ▸ | ESR1 | P03372 | 6/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.38 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.38 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30150247 | 0.83 | CA1 (0.43) | ESR2ESR1CA1CA2CA7 | |
| SCHEMBL17891164 | 0.83 | CA1 (0.43) | ESR2ESR1CA1CA2CA7 | |
| SCHEMBL17890603 | 0.81 | ESR1 (0.62) | ESR2ESR1PKMCA1CA2 | |
| SCHEMBL31164724 | 0.81 | ESR1 (0.62) | ESR2ESR1PKMCA1CA2 | |
| SCHEMBL17890573 | 0.78 | ESR2 (0.62) | ESR2CA1CA2CA7CA9 | |
| SCHEMBL29590263 | 0.78 | ESR2 (0.62) | ESR2CA1CA2CA7CA9 | |
| SCHEMBL14925173 | 0.77 | HRH3 (0.46) | ESR2CA1CA2CA7CA9 | |
| SCHEMBL10067649 | 0.77 | ESR2 (0.68) | ESR2ESR1PKMABHD6ERCC1 | |
| SCHEMBL31173299 | 0.77 | ESR2 (0.68) | ESR2ESR1PKMABHD6HDAC8 | |
| SCHEMBL2334651 | 0.77 | ESR2 (0.68) | ESR2ESR1PKMABHD6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | SHIONOGI & CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | GLP1R, GIPR, GCGR | ESR2 1015/4885ESR1 773/4885PKM 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.